Invokana’s New FDA Warning

FDA Lab 3407 - Photo by: The U.S. Food and Drug Aadministration - Source: Flickr Creative Commons

The first FDA warning on Invokana focused on the risk of ketoacidosis, a condition in which high blood acid levels can result in certain serious health circumstances, as stated by the FDA. FDA’s warning issued yesterday however brought forth an entirely different issue together with the drug.

This new warning from the FDA states that patients taking Invokana (canagliflozin) face a risk of bone fracture and decreased bone mineral density. The agency explained that patients may experience a break after just 12 weeks since starting their drug treatment. The drug’s warning label and adverse reaction list have been corrected to reflect the brand new information, as stated by the FDA.

When the first warning was issued in May of this year, the public had its first sign that taking canagliflozin for type II diabetes wasn’t without hazards. The first litigations were filed soon after. This really is a typical routine when an FDA alert goes public. People who experienced one isolated occasion begin to recognize their situation was part of a bigger routine. And that’s when people begin to step forward.

“Having represented American people and families in the wake of countless drug recalls and safety warnings, our company is aware of the very serious nature of dangerous drug claims. We’ve invested our business’s substantial resources to offering the finest legal representation available to individuals who believe they might have reasons for a Invokana litigation.”

Nationwide-famous lawyers in the realm of family and product liability law, these lawyers provide information and free case reviews for persons wishing to learn more about SGLT2 inhibitors lawsuits for heart attack, ketoacidosis, kidney troubles, and wrongful death allegations.

The first FDA Security Statement, entitled, “FDA warns that SGLT2 inhibitors for diabetes may cause a serious condition of too much acid in the blood”, was released on May 15, 2015.** The safety communicating referred to ketoacidosis as “a serious ailment” that “may require hospitalization”.* The symptoms of ketoacidosis include stomach pain, nausea, vomiting, difficulty breathing, confusion, and unusual fatigue or sleepiness.* Based on the FDA, other drugs in the class that was SGLT2 and Invokana are approved to be used to treat type 2 diabetes in adults.

[wp_ad_camp_3]

The security report issued yesterday is the outcome of more than two years of investigation.

These attorneys are now reviewing ketoacidosis claims for kidney issues, and other serious health problems associated with this drug. Invokana lawyers will provide a confidential case evaluation at no cost for individuals who suffered blood acid problems, kidney failure, or a different side effects while taking it. Individuals who meet this description may contact an attorney through the business’s website for a no-obligation consultation on whether they have reasons to file a claim. The firm’s  lawyers consider persons and also the family members of persons who match this description could be entitled to actual repayment for the harm and damages they sustained while producers and the manufacturing companies gained from their business.

 

REFERENCES
1. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
2. http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm